AvenCell Secures $112 Million to Transform Cancer Treatment
AvenCell Therapeutics, Inc., a prominent player in the clinical-stage cell therapy sector, has successfully secured $112 million in Series B financing. This substantial funding will be instrumental in advancing its proprietary Universal Switchable CAR-T cell therapy platform, which targets hematologic malignancies and autoimmune diseases.
Key Players in the Funding Round
This funding round was spearheaded by Novo Holdings, a global leader in life sciences investment. Joining them are several other notable investors including F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital, and NYBC Ventures, all collaborating alongside founding investor Blackstone Life Sciences. The notable participation of these investors reflects growing confidence in AvenCell's innovative approach to cancer treatment.
Enhancing Therapeutic Options
AvenCell focuses on developing both autologous and allogeneic switchable CAR-T cell therapies. The funding will facilitate the ongoing clinical validation of AvenCell’s advanced CAR-T cell platform, which allows for CAR-T cells to be switched "Off" and "On" even after administration. This feature is aimed at improving the safety and effectiveness of treatments for patients with challenging hematologic malignancies.
The current lead candidates from AvenCell's innovative portfolio include AVC-101, an autologous CAR-T cell therapy, and AVC-201, which is engineered using CRISPR technology for allogeneic applications. Both candidates are designed to target CD123, an antigen prevalent in Acute Myeloid Leukemia (AML) cells, addressing a significant medical need in a disease that often leaves patients with few treatment options.
Leadership Commentary on Progress and Vision
Andrew Schiermeier, Ph.D., the CEO of AvenCell, expressed enthusiasm about the company’s progress and the influence of its next-generation therapies on patient care. He stated that AvenCell aspires to redefine the standard of care in oncology through adaptable and readily available therapies that can effectively treat cancers and autoimmune diseases that have been particularly resistant to existing treatments. The backing from Novo Holdings and the consortium of new investors will play a critical role in accelerating these initiatives.
Michael Bauer from Novo Holdings emphasized the innovative nature of AvenCell's technology, noting that both AVC-101 and AVC-201 have demonstrated promising early results in safety and efficacy across their clinical trials. He conveyed confidence in AvenCell’s unique offerings and their potential to redefine the landscape of cell therapy.
Nihal Sinha from F-Prime Capital also shared his perspective, underscoring the significant advantages offered by AvenCell's switchable CAR-T platform. He highlighted the ability to adjust CAR-T cell activity after infusion, addressing essential regulatory and efficacy concerns prevalent in current therapies.
About AvenCell Therapeutics
The name AvenCell is derived from the French word “avenir,” signifying its mission to be the future of cell therapy. This innovative company is dedicated to combating difficult-to-treat cancers, particularly focusing on acute myeloid leukemia (AML) while also extending its research toward other hematologic malignancies.
AvenCell’s objective is to create allogeneic therapies that not only match but exceed the longevity of autologous treatments. By developing a universal and switchable construct, AvenCell ensures complete control over T cell functionality post-infusion, which significantly enhances scalability and efficiency compared to current therapeutic approaches.
Founded in 2021 by Blackstone Life Sciences in collaboration with other leading biotech entities, AvenCell operates its headquarters in Watertown with additional research and development facilities in Europe. The integration of advanced methodologies in their therapeutic developments suggests a promising future for AvenCell in the domain of hematological treatment options.
Frequently Asked Questions
What is AvenCell's main focus in therapies?
AvenCell primarily focuses on developing switchable CAR-T cell therapies targeting acute myeloid leukemia and other difficult-to-treat cancers.
How much funding did AvenCell raise?
AvenCell raised a total of $112 million in Series B funding led by Novo Holdings.
Who are the main investors involved?
Main investors include Novo Holdings, F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital, and NYBC Ventures.
What are the lead candidates for AvenCell's therapies?
The lead candidates are AVC-101, an autologous CAR-T cell therapy, and AVC-201, a CRISPR-engineered allogeneic CAR-T cell therapy.
How does AvenCell's technology improve treatment?
AvenCell’s switchable CAR-T technology allows for greater control over cell activity after treatment, enhancing both safety and efficacy compared to traditional therapies.
